Tyrosine kinase inhibitors in pulmonary arterial hypertension: A double-edge sword?

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 5, 2013, Pages 714-724

  Godinas, Laurent ^a   Guignabert, Christophe ^b,c,d   Seferian, Andrei ^b,c,d   Perros, Frederic ^b,c,d   Bergot, Emmanuel ^e,f   Sibille, Yves ^a   Humbert, Marc ^b,c,d   Montani, David ^b,c,d  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICÊTRE HOSPITAL   (France)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE CAEN   (France)

Author keywords

cardiotoxicity; dasatinib; imatinib; pulmonary arterial hypertension; receptor tyrosine kinase; sorafenib

Indexed keywords

BONE MORPHOGENETIC PROTEIN; DASATINIB; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVENTITIA; ALOPECIA; APOPTOSIS; ARTICLE; BLOOD VESSEL WALL; BONE MARROW; CARDIOTOXICITY; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE REGISTRY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE; HAND FOOT SYNDROME; HEMATOPOIETIC STEM CELL; HUMAN; INTIMA; LUNG FIBROBLAST; ONCOGENE C KIT; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SMOOTH MUSCLE FIBER; TREATMENT DURATION;

APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PULMONARY CIRCULATION; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES; THIAZOLES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884304618     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1356494     Document Type: Article

References (113)

1. Humbert M., Morrell N. W., Archer S. L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol: 2004; 43 (12, Suppl S): 13S 24S (Pubitemid 38759713)
2. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med: 2004; 351 14 1425 1436
3. Galiè N., Hoeper M. M., Humbert M., et al. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J: 2009; 34 6 1219 1263
4. Rai P. R., Cool C. D., King J. A., et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med: 2008; 178 6 558 564
5. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell: 2000; 100 1 57 70 (Pubitemid 30046295)
6. Sakao S., Tatsumi K. Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. Int J Cardiol: 2011; 147 1 4 12
7. Tu L., Dewachter L., Gore B., et al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol: 2011; 45 2 311 322
8. Tu L., De Man F. S., Girerd B., et al. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med: 2012; 186 7 666 676
9. Masri F. A., Xu W., Comhair S. A., et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol: 2007; 293 3 L548 L554 (Pubitemid 47358814)
10. Geraci M. W., Moore M., Gesell T., et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res: 2001; 88 6 555 562 (Pubitemid 32275790)
11. Lévy M., Maurey C., Celermajer D. S., et al. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol: 2007; 49 7 803 810 (Pubitemid 46240714)
12. Tuder R. M., Cool C. D., Yeager M., Taraseviciene-Stewart L., Bull T. M., Voelkel N. F. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med: 2001; 22 3 405 418
13. Tuder R. M., Chacon M., Alger L., et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol: 2001; 195 3 367 374
14. Lee S. D., Shroyer K. R., Markham N. E., Cool C. D., Voelkel N. F., Tuder R. M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest: 1998; 101 5 927 934 (Pubitemid 28125268)
15. Yeager M. E., Halley G. R., Golpon H. A., Voelkel N. F., Tuder R. M. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res: 2001; 88 1 E2 E11
16. Montani D., Perros F., Gambaryan N., et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med: 2011; 184 1 116 123
17. Stenmark K. R., Frid M. G., Yeager M., et al. Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change. Pulm Circ: 2012; 2 1 3 14
18. Davie N. J., Crossno J. T. Jr, Frid M. G., et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol: 2004; 286 4 L668 L678 (Pubitemid 38365049)
19. Gerasimovskaya E. V., Woodward H. N., Tucker D. A., Stenmark K. R. Extracellular ATP is a pro-angiogenic factor for pulmonary artery vasa vasorum endothelial cells. Angiogenesis: 2008; 11 2 169 182
20. Xu W., Koeck T., Lara A. R., et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A: 2007; 104 4 1342 1347 (Pubitemid 46184006)
21. Sakao S., Taraseviciene-Stewart L., Cool C. D., et al. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells. FASEB J: 2007; 21 13 3640 3652 (Pubitemid 350075152)
22. Sakao S., Tatsumi K., Voelkel N. F. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res: 2009; 10 95
23. Sakao S., Tatsumi K., Voelkel N. F. Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol: 2010; 43 6 629 634
24. Adnot S. Lessons learned from cancer may help in the treatment of pulmonary hypertension. J Clin Invest: 2005; 115 6 1461 1463 (Pubitemid 40814651)
25. de Man F. S., Tu L., Handoko M. L., et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med: 2012; 186 8 780 789
26. Guignabert C., Tu L., Izikki M., et al. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. FASEB J: 2009; 23 12 4135 4147
27. McMurtry M. S., Archer S. L., Altieri D. C., et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest: 2005; 115 6 1479 1491 (Pubitemid 40814657)
28. Davies R. J., Holmes A. M., Deighton J., et al. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Am J Physiol Lung Cell Mol Physiol: 2012; 302 6 L604 L615
29. Zhang S., Fantozzi I., Tigno D. D., et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol: 2003; 285 3 L740 L754 (Pubitemid 37022876)
30. Jeffery T. K., Wanstall J. C. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther: 2001; 92 1 1 20 (Pubitemid 34032020)
31. Stenmark K. R., Fagan K. A., Frid M. G. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res: 2006; 99 7 675 691 (Pubitemid 44498302)
32. Das M., Dempsey E. C., Reeves J. T., Stenmark K. R. Selective expansion of fibroblast subpopulations from pulmonary artery adventitia in response to hypoxia. Am J Physiol Lung Cell Mol Physiol: 2002; 282 5 L976 L986 (Pubitemid 34654614)
33. Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev: 2004; 15 4 197 204 (Pubitemid 38781045)
34. Heldin C. H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev: 1999; 79 4 1283 1316 (Pubitemid 29473317)
35. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem: 1994; 269 51 32023 32026
36. Grimminger F., Schermuly R. T. PDGF receptor and its antagonists: role in treatment of PAH. Adv Exp Med Biol: 2010; 661 435 446
37. Balasubramaniam V., Le Cras T. D., Ivy D. D., Grover T. R., Kinsella J. P., Abman S. H. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol: 2003; 284 5 L826 L833 (Pubitemid 36459029)
38. Jankov R. P., Kantores C., Belcastro R., et al. A role for platelet-derived growth factor beta-receptor in a newborn rat model of endothelin-mediated pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol: 2005; 288 6 L1162 L1170 (Pubitemid 40695443)
39. Humbert M., Monti G., Fartoukh M., et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J: 1998; 11 3 554 559 (Pubitemid 28194842)
40. Perros F., Montani D., Dorfmüller P., et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med: 2008; 178 1 81 88 (Pubitemid 351919196)
41. Wedgwood S., Devol J. M., Grobe A., et al. Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res: 2007; 61 1 32 36 (Pubitemid 46352312)
42. Arcot S. S., Fagerland J. A., Lipke D. W., Gillespie M. N., Olson J. W. Basic fibroblast growth factor alterations during development of monocrotaline-induced pulmonary hypertension in rats. Growth Factors: 1995; 12 2 121 130
43. Benisty J. I., McLaughlin V. V., Landzberg M. J., et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest: 2004; 126 4 1255 1261 (Pubitemid 39391258)
44. Izikki M., Guignabert C., Fadel E., et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest: 2009; 119 3 512 523
45. Normanno N., Bianco C., De Luca A., Salomon D. S. The role of EGF-related peptides in tumor growth. Front Biosci: 2001; 6 D685 D707
46. Holsinger F. C., Doan D. D., Jasser S. A., et al. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res: 2003; 9 8 3183 3189 (Pubitemid 36993281)
47. Lurje G., Lenz H. J. EGFR signaling and drug discovery. Oncology: 2009; 77 6 400 410
48. Le Cras T. D., Hardie W. D., Fagan K., Whitsett J. A., Korfhagen T. R. Disrupted pulmonary vascular development and pulmonary hypertension in transgenic mice overexpressing transforming growth factor-alpha. Am J Physiol Lung Cell Mol Physiol: 2003; 285 5 L1046 L1054 (Pubitemid 37310094)
49. Merklinger S. L., Jones P. L., Martinez E. C., Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation: 2005; 112 3 423 431 (Pubitemid 41022085)
50. Dahal B. K., Cornitescu T., Tretyn A., et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med: 2010; 181 2 158 167
51. Tuder R. M., Yun J. H. Vascular endothelial growth factor of the lung: friend or foe. Curr Opin Pharmacol: 2008; 8 3 255 260
52. Kasahara Y., Tuder R. M., Taraseviciene-Stewart L., et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest: 2000; 106 11 1311 1319
53. Partovian C., Adnot S., Eddahibi S., et al. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol: 1998; 275 6, Pt 2 H1948 H1956
54. Campbell A. I., Zhao Y., Sandhu R., Stewart D. J. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation: 2001; 104 18 2242 2248 (Pubitemid 33043307)
55. Taraseviciene-Stewart L., Kasahara Y., Alger L., et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J: 2001; 15 2 427 438 (Pubitemid 32141434)
56. Taraseviciene-Stewart L., Scerbavicius R., Choe K. H., et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol: 2006; 291 4 L668 L676 (Pubitemid 44498478)
57. Grover T. R., Parker T. A., Zenge J. P., Markham N. E., Kinsella J. P., Abman S. H. Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol: 2003; 284 3 L508 L517 (Pubitemid 36231729)
58. Sata M., Saiura A., Kunisato A., et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med: 2002; 8 4 403 409 (Pubitemid 34407037)
59. Gambaryan N., Perros F., Montani D., Cohen-Kaminsky S., Mazmanian G. M., Humbert M. Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. Eur Respir J: 2010; 36 5 1209 1211
60. Gambaryan N., Perros F., Montani D., et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J: 2011; 37 6 1392 1399
61. Perros F., Dorfmüller P., Souza R., et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J: 2007; 29 3 462 468 (Pubitemid 46372091)
62. Mitani Y., Ueda M., Maruyama K., et al. Mast cell chymase in pulmonary hypertension. Thorax: 1999; 54 1 88 90 (Pubitemid 29103760)
63. Heath D., Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol: 1991; 44 12 1003 1006
64. Dahal B. K., Kosanovic D., Kaulen C., et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res: 2011; 12 60
65. Metz M., Grimbaldeston M. A., Nakae S., Piliponsky A. M., Tsai M., Galli S. J. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev: 2007; 217 304 328 (Pubitemid 46718153)
66. Okayama Y., Ra C., Saito H. Role of mast cells in airway remodeling. Curr Opin Immunol: 2007; 19 6 687 693 (Pubitemid 350236804)
67. Guignabert C., Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J: 2013; 41 1 3 4
68. Oda Y., Renaux B., Bjorge J., Saifeddine M., Fujita D. J., Hollenberg M. D. cSrc is a major cytosolic tyrosine kinase in vascular tissue. Can J Physiol Pharmacol: 1999; 77 8 606 617
69. Courboulin A., Paulin R., Giguère N. J., et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med: 2011; 208 3 535 548
70. Nagaraj C., Tang B., Bálint Z., et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J: 2013; 41 1 85 95
71. Pullamsetti S. S., Berghausen E. M., Dabral S., et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol: 2012; 32 6 1354 1365
72. Grünwald V., Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst: 2003; 95 12 851 867 (Pubitemid 36833877)
73. O'Connell C., O'Callaghan D. S., Gaine S. New drugs for pulmonary hypertension. European Respiratory Monograph: 2012; 57 233 246
74. Abe K., Toba M., Alzoubi A., et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol: 2011; 45 4 804 808
75. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature: 2001; 411 6835 355 365 (Pubitemid 32467045)
76. Schermuly R. T., Dony E., Ghofrani H. A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest: 2005; 115 10 2811 2821 (Pubitemid 41434408)
77. Patterson K. C., Weissmann A., Ahmadi T., Farber H. W. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med: 2006; 145 2 152 153 (Pubitemid 46780594)
78. Ghofrani H. A., Seeger W., Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med: 2005; 353 13 1412 1413 (Pubitemid 41362714)
79. Souza R., Sitbon O., Parent F., Simonneau G., Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax: 2006; 61 8 736 (Pubitemid 44211786)
80. Ghofrani H. A., Morrell N. W., Hoeper M. M., et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med: 2010; 182 9 1171 1177
81. Humbert M. Impression, sunset. Circulation: 2013; 127 10 1098 1100
82. Hoeper M. M., Barst R. J., Bourge R. C., et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation: 2013; 127 10 1128 1138
83. Daniels C. E., Lasky J. A., Limper A. H., Mieras K., Gabor E., Schroeder D. R. Imatinib-IPF Study Investigators Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med: 2010; 181 6 604 610
84. Henkens I. R., Hazenoot T., Boonstra A., et al. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J: 2012
85. Simonneau G., Hwang L. J., Teal S., Galie N. Incidence of subdural hematoma in patients with pulmonary arterial hypertension (PAH) in two randomized controlled clinical trials. Eur Respir J: 2012; 40 (Suppl. 56): 941
86. Llovet J. M., Ricci S., Mazzaferro V., et al. SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med: 2008; 359 4 378 390
87. Escudier B., Eisen T., Stadler W. M., et al. TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med: 2007; 356 2 125 134 (Pubitemid 46089673)
88. Yu C., Bruzek L. M., Meng X. W., et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene: 2005; 24 46 6861 6869 (Pubitemid 41509409)
89. Klein M., Schermuly R. T., Ellinghaus P., et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation: 2008; 118 20 2081 2090
90. Moreno-Vinasco L., Gomberg-Maitland M., Maitland M. L., et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics: 2008; 33 2 278 291 (Pubitemid 351629535)
91. Gomberg-Maitland M., Maitland M. L., Barst R. J., et al. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther: 2010; 87 3 303 310
92. Maurer B., Reich N., Juengel A., et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis: 2012; 71 8 1382 1387
93. Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH). Available at: http://www.clinicaltrials.gov. Identifier NCT01179737
94. Atallah E., Durand J. B., Kantarjian H., Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood: 2007; 110 4 1233 1237 (Pubitemid 47281421)
95. Cohen M. H., Williams G., Johnson J. R., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res: 2002; 8 5 935 942 (Pubitemid 34520420)
96. Kerkelä R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med: 2006; 12 8 908 916 (Pubitemid 44175142)
97. Atallah E. Nilotinib cardiac toxicity: should we still be concerned? Leuk Res: 2011; 35 5 577 578
98. Atkins M., Jones C. A., Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov: 2006; 5 4 279 280
99. Demetri G. D., van Oosterom A. T., Garrett C. R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet: 2006; 368 9544 1329 1338 (Pubitemid 44528723)
100. Chu T. F., Rupnick M. A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet: 2007; 370 9604 2011 2019 (Pubitemid 350236338)
101. Khakoo A. Y., Kassiotis C. M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer: 2008; 112 11 2500 2508
102. Lombardo L. J., Lee F. Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem: 2004; 47 27 6658 6661 (Pubitemid 40053752)
103. Kantarjian H., Shah N. P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med: 2010; 362 24 2260 2270
104. Kantarjian H. M., Shah N. P., Cortes J. E., et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood: 2012; 119 5 1123 1129
105. Orlandi E. M., Rocca B., Pazzano A. S., Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res: 2012; 36 1 e4 e6
106. Dumitrescu D., Seck C., ten Freyhaus H., Gerhardt F., Erdmann E., Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J: 2011; 38 1 218 220
107. Mattei D., Feola M., Orzan F., Mordini N., Rapezzi D., Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant: 2009; 43 12 967 968
108. Rasheed W., Flaim B., Seymour J. F. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res: 2009; 33 6 861 864
109. Montani D., Bergot E., Günther S., et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation: 2012; 125 17 2128 2137
110. Mandegar M., Fung Y. C., Huang W., Remillard C. V., Rubin L. J., Yuan J. X. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res: 2004; 68 2 75 103 (Pubitemid 39093882)
111. Rix U., Hantschel O., Dürnberger G., et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood: 2007; 110 12 4055 4063 (Pubitemid 350248462)
112. Zakrzewski D., Seferynska I., Warzocha K., Hryniewiecki T. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia. Int J Hematol: 2012; 96 1 132 135
113. Keller-V Amsberg G., Brümmendorf T. H. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther: 2012; 12 9 1121 1127